Background:Interphase fluorescence in situ hybridization(FISH)of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived hom...Background:Interphase fluorescence in situ hybridization(FISH)of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog(MYCN)amplification in patients with bone marrow metastatic neuroblastoma.MYCN amplification alone,however,is insufficient for pretreatment risk stratification.Chromosome band 11q23 deletion has recently been included in the risk stratification of neuroblastoma.In the present study,we aimed to evaluate the biological characteristics and prog-nostic impact of 11q23 deletion and MYCN amplification in patients with bone marrow metastatic neuroblastoma.Methods:We analyzed the MYCN and 11q23 statuses of 101 patients with bone marrow metastatic neuroblastoma using interphase FISH of bone marrow cells.We specifically compared the biological characteristics and prognostic impact of both aberrations.Results:MYCN amplification and 11q23 deletion were seen in 12(11.9%)and 40(39.6%)patients.The two mark-ers were mutually exclusive.MYCN amplification occurred mainly in patients with high lactate dehydrogenase(LDH)and high neuron-specific enolase(NSE)levels(both P<0.001),and MYCN-amplified patients had more events(tumor relapse,progression,or death)than MYCN-normal patients(P=0.004).11q23 deletion was associated only with age(P=0.001).Patients with MYCN amplification had poorer outcomes than those with normal MYCN(3-year event-free survival[EFS]rate:8.3±8.0%vs.43.8±8.5%,P<0.001;3-year overall survival[OS]rate:10.4±9.7%vs.63.5%±5.7%,P<0.001).11q23 deletion reflected a poor prognosis only for patients with normal MYCN(3-year EFS rate:34.3±9.5%vs.53.4±10.3%,P=0.037;3-year OS rate:42.9±10.4%vs.75.9±6.1%,P=0.048).Those with both MYCN amplification and 11q23 deletion had the worst outcome(P<0.001).Conclusions:Chromosome band 11q23 deletion predicts poor prognosis only in bone marrow metastatic neuroblastoma patients without MYCN amplification.Combined assessment of the two markers was much superior to single展开更多
To establish optimal reference values for recovered immune cell subsets, we prospectively investigated post-transplant immune reconstitution （IR） in 144 patients who received allogeneic stem ceil transplantation （a...To establish optimal reference values for recovered immune cell subsets, we prospectively investigated post-transplant immune reconstitution （IR） in 144 patients who received allogeneic stem ceil transplantation （alio- SCT） and without showing any of the following events： poor graft function, grades II-IV acute graft-versus-host disease （GVHD）, serious chronic GVHD, serious bacterial infection, invasive fungal infection, or relapse or death in the first year after transplantation. IR was rapid in monocytes, intermediate in lymphocytes, CD3~ T cells, CD8~ T cells, and CD19~ B cells, and very slow in CD4~ T cells in the entire patient cohort. Immune recovery was generally faster under HLA-matched sibling donor transplantation than under haploidentical transplantation. Results suggest that patients with an IR comparable to the reference values display superior survival, and the levels of recovery in immune ceils need not reach those in healthy donor in the first year after transplantation. We suggest that data from this recipient cohort should be used as reference values for post-transplant immune ceil counts in patients receiving HSCT.展开更多
Importance:There is a high incidence of iron deficiency in children worldwide.Notably,however,while iron deficiency is the most common cause of anemia,little is known about the prevalence and different types of iron d...Importance:There is a high incidence of iron deficiency in children worldwide.Notably,however,while iron deficiency is the most common cause of anemia,little is known about the prevalence and different types of iron deficiency in neuroblastoma patients.Objective:The aim of the present study was to investigate the prevalence of iron deficiency in patients newly diagnosed with neuroblastoma.Methods:A total of 195 newly diagnosed neuroblastoma patients from November 2015 to January 2018 were analyzed retrospectively.The survival analysis was estimated by the Kaplan-Meier method.Results:Of the 195 neuroblastoma patients included in the study,121(62.1%)had iron deficiency,55(28.2%)had absolute iron deficiency,and 66(33.9%)had functional iron deficiency.Being aged≥18 months,tumor originating in the abdomen,International Neuroblastoma Risk Group Staging System M,high-risk neuroblastoma,lactate dehydrogenase≥1500 U/L,neuron-specific enolase≥100 U/L,unfavorable histologic category,MYCN amplification,chromosome 1p loss,and bone marrow metastasis were associated with significantly higher rates of functional iron deficiency(P<0.05).Interpretation:Functional iron deficiency at the time of initial neuroblastoma diagnosis predicted lower event-free survival.Long-term effects of iron supplementation in neuroblastoma patients with different types of iron deficiency need to be further studied.展开更多
基金This work was supported by Capital’s Funds for Health Improvement and Research(2018-2-2095).
文摘Background:Interphase fluorescence in situ hybridization(FISH)of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog(MYCN)amplification in patients with bone marrow metastatic neuroblastoma.MYCN amplification alone,however,is insufficient for pretreatment risk stratification.Chromosome band 11q23 deletion has recently been included in the risk stratification of neuroblastoma.In the present study,we aimed to evaluate the biological characteristics and prog-nostic impact of 11q23 deletion and MYCN amplification in patients with bone marrow metastatic neuroblastoma.Methods:We analyzed the MYCN and 11q23 statuses of 101 patients with bone marrow metastatic neuroblastoma using interphase FISH of bone marrow cells.We specifically compared the biological characteristics and prognostic impact of both aberrations.Results:MYCN amplification and 11q23 deletion were seen in 12(11.9%)and 40(39.6%)patients.The two mark-ers were mutually exclusive.MYCN amplification occurred mainly in patients with high lactate dehydrogenase(LDH)and high neuron-specific enolase(NSE)levels(both P<0.001),and MYCN-amplified patients had more events(tumor relapse,progression,or death)than MYCN-normal patients(P=0.004).11q23 deletion was associated only with age(P=0.001).Patients with MYCN amplification had poorer outcomes than those with normal MYCN(3-year event-free survival[EFS]rate:8.3±8.0%vs.43.8±8.5%,P<0.001;3-year overall survival[OS]rate:10.4±9.7%vs.63.5%±5.7%,P<0.001).11q23 deletion reflected a poor prognosis only for patients with normal MYCN(3-year EFS rate:34.3±9.5%vs.53.4±10.3%,P=0.037;3-year OS rate:42.9±10.4%vs.75.9±6.1%,P=0.048).Those with both MYCN amplification and 11q23 deletion had the worst outcome(P<0.001).Conclusions:Chromosome band 11q23 deletion predicts poor prognosis only in bone marrow metastatic neuroblastoma patients without MYCN amplification.Combined assessment of the two markers was much superior to single
文摘To establish optimal reference values for recovered immune cell subsets, we prospectively investigated post-transplant immune reconstitution （IR） in 144 patients who received allogeneic stem ceil transplantation （alio- SCT） and without showing any of the following events： poor graft function, grades II-IV acute graft-versus-host disease （GVHD）, serious chronic GVHD, serious bacterial infection, invasive fungal infection, or relapse or death in the first year after transplantation. IR was rapid in monocytes, intermediate in lymphocytes, CD3~ T cells, CD8~ T cells, and CD19~ B cells, and very slow in CD4~ T cells in the entire patient cohort. Immune recovery was generally faster under HLA-matched sibling donor transplantation than under haploidentical transplantation. Results suggest that patients with an IR comparable to the reference values display superior survival, and the levels of recovery in immune ceils need not reach those in healthy donor in the first year after transplantation. We suggest that data from this recipient cohort should be used as reference values for post-transplant immune ceil counts in patients receiving HSCT.
基金The study was funded by Beijing Municipal Science and Technology Commission(Grant No.Z151100004015159).
文摘Importance:There is a high incidence of iron deficiency in children worldwide.Notably,however,while iron deficiency is the most common cause of anemia,little is known about the prevalence and different types of iron deficiency in neuroblastoma patients.Objective:The aim of the present study was to investigate the prevalence of iron deficiency in patients newly diagnosed with neuroblastoma.Methods:A total of 195 newly diagnosed neuroblastoma patients from November 2015 to January 2018 were analyzed retrospectively.The survival analysis was estimated by the Kaplan-Meier method.Results:Of the 195 neuroblastoma patients included in the study,121(62.1%)had iron deficiency,55(28.2%)had absolute iron deficiency,and 66(33.9%)had functional iron deficiency.Being aged≥18 months,tumor originating in the abdomen,International Neuroblastoma Risk Group Staging System M,high-risk neuroblastoma,lactate dehydrogenase≥1500 U/L,neuron-specific enolase≥100 U/L,unfavorable histologic category,MYCN amplification,chromosome 1p loss,and bone marrow metastasis were associated with significantly higher rates of functional iron deficiency(P<0.05).Interpretation:Functional iron deficiency at the time of initial neuroblastoma diagnosis predicted lower event-free survival.Long-term effects of iron supplementation in neuroblastoma patients with different types of iron deficiency need to be further studied.
